“We continue to believe in a positive benefit-risk profile of COVID-19 vaccine,” Johnson & Johnson said in response to the statement released after the US Centers for Disease Control and Prevention (CDC) Advisory Committee meeting.
Earlier on, the US CDC extended the halt on the distribution of the vaccine amid a lack of more data to assess the risk.
Share
